Vaccination with AstraZeneca’s COVID-19 vaccine can lead to blood clots in very rare cases, according to new research published Friday in the New England Journal of Medicine.
This is the latest scientific indicator that this company concerns the appearance of blood clots so far more likely to affect women; however, the number of people who develop blood clotting disorders is considered very rare.
The medical journal on Friday published two articles: one examined five Norwegian health care workers who developed blood clots 7 to 10 days after receiving the first dose of AstraZeneca vaccine, and other was written by German scientists who examined 11 patients in Germany and Austria who reported having blood clots after injecting the drug. In this case, blood clots appear 5 to 16 days after vaccination.
Both articles mention what they call “vaccine-induced thrombocytopenia” (VITT) as the reason behind the rare blood clotting disorder, with German researchers suggesting this should be the naming of this disorder.
The Norwegian researchers concluded: “The findings in our study indicate that VITT may occur more frequently than previous studies, in which the safety of the vaccine ChAdOx1 nCoV-19 has been investigated, ”concluded Norwegian researchers.
Since reports of fatal blood clots occasionally appear, European countries like France and Germany have stopped using the vaccine, developed in collaboration with Oxford University. This vaccine has not been authorized in the United States, though company recently said they planned to search Emergency authorization from the Food and Drug Administration.
The European Pharmaceutical Authority said Wednesday that blood clots should be listed as Side effects are rare for vaccines and the World Health Organization say the same day that it was “plausible” there was a link between the vaccine and reports of blood clots, although it was not confirmed at the time.
Shares in AstraZeneca are down 0.2% on the year, while the S&P 500 is broader
an increase of 8.5%.